| Inclusion and exclusion criteria
The inclusion criteria were as follow: (a) randomized controlled trials; (b) patients with ACI who met the fulfilment of the World Health Organization (WHO) cerebral infarction criteria 9 ; (c) patients aged 18 years and above; (d) provision of effective number of cases for measurement of outcomes; (e) absence of serious gastrointestinal tract diseases and drug allergies which affect drug absorption and (f) studies that used aspirin alone as control group, while the observation group was one of aspirin combinations for the treatment of ACI.
The exclusion criteria were as follows: (a) studies with provision of repeated or incomplete data; (b) research types that were animal-based experiments, case reports, summaries of experience, theoretical discussions and reviews; (c) purely descriptive studies with no control group; (d) patients with severe heart, lung, liver or kidney damage, tumour or immune diseases and (e) patients with severe mental illness or dementia.
| Efficacy evaluation criteria
This study was based on the "Criteria for Clinical Neurological Deficits in Stroke Patients" adopted by the Fourth China Cerebrovascular
Disease Conference in 1995. 10 The curative effect was based on the integral value of the neurological deficit before and after treatment as follows: (a) basic recovery (BR): functional impairment score reduced by 91%-100%, while the degree of disability was 0; (b) significant progress (SP): functional impairment score reduced by 46%-90%, while the degree of disability was between 1 and 3; (c) progress (P):
the functional impairment score reduced by 18%-45%; (d) no change:
the functional impairment score decreased or increased by <18%; TA B L E 1 (Continued) (e) deterioration: score of functional impairment increased by >18%
F I G U R E 1 Flow diagram of the selection details of included publications
and (f) death: the total effective cases (TEC) were calculated thus, TEC = BR + SP + P.
All analyses were adapted from previous published work. Thus, no ethical approval and patient consent were required. 
| Data extraction and quality evaluation

| Statistical analysis
The network, evidence contribution, predictive interval (PrI), funnel and ranking plots were constructed using commands of the network package in stata (13.0). The efficacy of interventions was ranked based on the value of surface under the cumulative ranking (SUCRA) curve. The selected indicators were count data, while OR was used as the combined effect, and the confidence interval (CI) was set at 95%. Values of P < 0.05 were considered statistically significant.
| RE SULTS
| Characteristics of included studies
A total of 103 randomized controlled trials involving 13 317 patients were ultimately included in the analysis. Figure 1 shows the selection detail of publications included, while their basic characteristics are presented in Tables 1 and 2 , respectively.
| Network meta-analysis
| Network plot of six different aspirin combinations
Of the 103 publications, studies on the combination of aspirin with clopidogrel were the most frequent, while those on aspirin + cilostazol were least frequent. The aspirin-alone group had the highest number of subjects, while aspirin + cilostazol had the lowest number of subjects ( Figure 2 ). A, aspirin; B, aspirin + atorvastatin; C, aspirin + ozagrel sodium; D, aspirin + LMWH; E, aspirin + clopidogrel; F, aspirin + cilostazol; G, aspirin + ginkgo damo.
TA B L E 2 Classification of included studies
F I G U R E 2 Network plot of different interventions for the treatment of acute cerebral infarction. The size of the point in the network graph is proportional to the number of subjects, while the thickness of the line is proportional to the number of studies. Abbreviations: A, aspirin; B, aspirin + atorvastatin; C, aspirin + ozagrel sodium; D, aspirin + low molecular weight heparin; E, aspirin + clopidogrel; F, aspirin + cilostazol and G, aspirin + ginkgo damo (Figure 3) . 
| Predictive interval plot
Meta-analysis results showed that the pooled OR and 95% CI of ACI improvement compared with aspirin alone were 3.98 (2.49-6.36) for aspirin + atorvastatin, 2.78 (1.98-3.90) for aspirin + ozagrel sodium,
(2.07-5.71) for aspirin + ginkgo damo, respectively, which indicates a significant difference in efficacy. For the comparison between aspirin combinations, no significant differences were found. The OR for the network estimates along with 95% CI and PrI is presented in Figure 4 .
| Publication bias
Regarding publication bias, all the outcomes in the study were not exactly symmetrical ( Figure 5 ), suggesting that the publication bias may have existed.
| Ranking plot
The distribution of probabilities for each treatment being ranked for their efficacy in ACI according to SUCRA values is presented in Table 3 and Figure 6 . The order of SUCRA values for different aspirin combinations was as follows: aspirin + LMWH (79.1), aspirin + atorvastatin (70.8), aspirin + clopidogrel (59.9), aspirin + cilostazol (56.4), aspirin + ginkgo damo (54.1) and aspirin + ozagrel sodium (29.7). Therefore, the combination of aspirin with LMWH had the highest probability of being the best intervention option in terms of clinical efficacy.
| D ISCUSS I ON
This study analyzed six aspirin combinations and conducted a pair- defibrination, expansion and neuroprotective drugs. 13, 14 In addition to thrombolytic therapy, the ideal drugs for preventing and treating cerebral infarction are antiplatelet drugs, such as aspirin. 15 The largest meta-analysis to date indicates that aspirin is effective in the early treatment and prevention of cerebral infarction, making it a classic drug for the treatment and prevention of ischaemic stroke. 16 Aspirin is a potent inhibitor of platelet aggregation, and its antithrombotic effect is mainly due to the irreversible inhibition of the acetylated cyclooxygenase (COX-1), 17 which in turn inhibits the production of prostaglandin H 2 (PGH 2 ) in platelets. Aspirin also inhibits PG synthase in vascular endothelial cells, resulting in a decrease in PGI 2 production, partially offsetting its antithrombotic effects. In recent years, the anticoagulant drug LMWH has gained clinical prominence due to its high antithrombotic activity.
In the present study, a combination of aspirin with LMWH was of vascular endothelial cells. 21 The side effects of the six different aspirin combinations include dizziness, heart palpitations, nausea, vomiting, intracranial haemorrhage, gastrointestinal haemorrhage, mucocutaneous haemorrhage and abnormalities in blood routine, urine routines, liver function and kidney function. Cases of these adverse reactions were rarely reported in the studies evaluated in this paper, so these outcomes were not analyzed. In a TMA with five trials and short-term follow-up, no bleeding was reported in the group that received a combination of aspirin with clopidogrel.
This finding appeared to suggest that the regime of aspirin combination medications for a short time may be safe and more effective in the acute phase of ACI (the period of high risk of stroke after transient ischaemic attack).
22
TMAs have been used to study the combination of aspirin with other drugs in the treatment of ACI. 23, 24 While TMA only compares one or two drugs, NMA is used when more than two drugs are involved. 25 
| WHAT IS NE W AND CON CLUS I ON
The combination of aspirin with LMWH is the best option out of the six aspirin combinations studied for the treatment of ACI, while the combination of aspirin with ozagrel sodium is the least effective.
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